Diabetic cardiomyopathy: Pathophysiological mechanisms and cardiac dysfuntion

Human and Experimental Toxicology

Volumn 32, Issue 6, 2013, Pages 571-590

  Goyal, B R ^a   Mehta, A A ^b  

^a NIRMA UNIVERSITY   (India)

^b L M COLLEGE OF PHARMACY   (India)

Author keywords

Diabetic cardiomyopathy; diastolic dysfunction; metabolic disturbances; structural changes; systolic dysfunction

Indexed keywords

FATTY ACID; GLUCOSE; PYRUVIC ACID; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; AUTONOMIC NEUROPATHY; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; DIASTOLIC DYSFUNCTION; ENDOTHELIAL DYSFUNCTION; ENERGY RESOURCE; GLUCOSE INTOLERANCE; GLUCOSE UTILIZATION; GLYCOLYSIS; HEART MUSCLE FIBROSIS; HUMAN; METABOLIC DISORDER; MICROANGIOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTOLIC DYSFUNCTION;

DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; METABOLIC DISTURBANCES; STRUCTURAL CHANGES; SYSTOLIC DYSFUNCTION;

DIABETIC CARDIOMYOPATHIES; DIABETIC NEUROPATHIES; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HUMANS; MYOCARDIUM;

EID: 84878282881     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112450885     Document Type: Review

References (147)

1. http://www.who.int/mediacentre/factsheets/fs312/en/(accessed on 28 March 2011).
2. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 ; 21: 1414-1431
3. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972 ; 30: 595-602
4. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidences, mechanism and therapeutic implications. Endocr Rev. 2004 ; 25: 543-567
5. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005 ; 105: 315e8
6. Mishra TK, Rath PK. Diabetic cardiomyopathy: evidences, pathophysiology, and therapeutic considerations. JIACM. 2005 ; 6: 312-318
7. Mokuda O, Sakamoty Y, Ikeda J, Mashiba H. Effects of anoxia and low free fatty acids in myocardial energy metabolism in streptozotoem-diabetic rates. Ann Nutr Metab. 1990 ; 34: 259-265
8. Rodrigues B, Cam MC, McNeil JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem. 1998 ; 180: 53-57
9. Russell RR, Yin R, Caplan MJ, Hu X, Ren J, Shulman GI, et al. Additive effects of hyperinsulinemia and ischemia on myocardial GLUT 1 and GLUT 4 translocation in vivo. Circulation. 1998 ; 98: 2180-2186
10. Liedtke AJ, De Maison L, Eggleston AM, Cohen LM, Nellis SH. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res. 1988 ; 62: 535-542
11. Lopaschuk GD, Russell JC. Myocardial function and energy substrate metabolism in the insulin-resistant JCR: LA corpulent rat. J Appl Physiol. 1991 ; 71: 1302-1308
12. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab. 2000 ; 279: E1104 - E1113
13. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol. 2002 ; 283: H976 - H982
14. Chatham JC, Gao ZP, Bonen A, Forder JR. Preferential inhibition of lactate oxidation relative to glucose oxidation in the rat heart following diabetes. Cardiovasc Res. 1999 ; 43: 96-106
15. Hall JL, Stanley WC, Lopaschuk GD, Wisneski JA, Pizzurro RD, Hamilton CD, et al. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol. 1996 ; 271: H2320 - H2329
16. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci. 2004 ; 107: 539-557
17. Nakayama H, Morozumi T, Nanto S, Shimonagata T, Ohara T, Takano Y, et al. Abnormal myocardial free fatty acid utilization deteriorates with morphological changes in the hypertensive heart. Jpn Circ J. 2001 ; 65: 783-787
18. Yazaki Y, et al. Assessment of myocardial fatty acid abnormalities in patients with idiopathic dilated cardiomyopathy using I123 BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart. 1999 ; 81: 153-159
19. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997 ; 34: 25-33
20. Zhou Y, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA. 2000 ; 97: 1794-1789
21. Malone JI, Schocken DD, Morrison AD, Gilbert- Barness E. Diabetic cardiomyopathy and carnitine deficiency. J Diabetes Complications. 1999 ; 13: 86-90
22. Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M. Myocardial mechanical and myosin isoenzyme alterations in streptozotocin-diabetic rats. Jpn Heart J. 1988 ; 29: 455-463
23. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, et al. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol. 2002 ; 282: H138 - H148
24. Malhotra A, Sanghi V. Regulation of contractile proteins in diabetic heart. Cardiovasc Res. 1997 ; 34: 34-40
25. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002 ; 51: 1166-1171
26. Kotsanas G, Delbridge LM, Wendt IR. Stimulus interval-dependent differences in Ca2+ transients and contractile responses of diabetic rat cardiomyocytes. Cardiovasc Res. 2000 ; 46: 450-462
27. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res. 1998 ; 40: 239-247
28. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic dysfunction in patients with diabetes. Diabetes Care. 1999 ; 22: 1186-1190
29. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001 ; 18: 945-959
30. Xia P, Inoguchi T, Kern TS, Oates Engerman R, King G. Characterisation of the mechanism for the chronic activation of diacyl-glycerol protein kinase C pathway in diabetes and hyperglactosemia. Diabetes. 1994 ; 43: 1122-1129
31. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochem Biophys Acta. 1996 ; 10: 709-720
32. Giles TD, Sander GE. Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. Cardiol Clin. 2004 ; 22: 553-568
33. Min W, Bin ZW, Quan ZB, Hui ZJ, Sheng FG. The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol. 2009 ; 8: 8
34. Schorlemmer A, Matter ML, Shohet RV. Cardioprotective signaling by endothelin. Trends Cardiovasc Med. 2008 ; 18: 233-239
35. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol. 1983 ; 244: E528 - E535
36. Giacomelli F, Wiener J.. Primary myocardial disease in the diabetic mouse. An ultrastructural study. Lab Invest. 1979 ; 40: 460-473
37. Regan TJ, Wu CF, Yeh CK, Oldewurtel HA, Haider B. Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res. 1981 ; 49: 1268-1277
38. Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA, et al. Myocyte death in the failing human heart is gender dependent. Circ Res. 1999 ; 85: 856-866
39. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 1998 ; 82: 1111-1129
40. Anversa P, Kajstura J. Myocyte cell death in the diseased heart. Circ Res. 1998 ; 82: 1231-1233
41. Gerschenson LE, Rotello RJ. Apoptosis: a different type of cell death. FASEB J. 1992 ; 6: 2450-2455
42. Anversa P, Leri A, Beltrami CA, Guerra S, Kajstura J. Myocyte death and growth in the failing heart. Lab Invest. 1998 ; 78: 767-786
43. Li B, Setoguchi M, Wang X, Andreoli AM, Leri A, Malhotra A, et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res. 1999 ; 84: 1007-1019
44. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991 ; 83: 1849-1865
45. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A. Myocardial cell death in human diabetes. Circ Res. 2000 ; 87: 1123-1132
46. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes. 2001 ; 50: 2363-2375
47. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycaemia induced apoptosis in mouse myocardium: mitochondrial C-mediated caspase- 3 activation pathway. Diabetes. 2002 ; 51: 1938-1948
48. Schaffer SW, Croft CB, Solodushko V. Cardioprotective effect of chronic hyperglycemia: effect on hypoxia-induced apoptosis and necrosis. Am J Physiol Heart Circ Physiol. 2000 ; 278: H1948 - H1954
49. Chen S, et al. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol. 2000 ; 32: 621-1629
50. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest. 2000 ; 80: 513-527
51. Bojestig M, Nystrom FH, Arnqvist HJ, Ludvigsson J, Karlberg BE. The renin-angiotensin-aldosterone system is suppressed in adults with type 1 diabetes. J Renin Angiotensin Aldosterone Syst. 2000 ; 1: 353-356
52. Sechi LA, Griffin CA, Schambelan M. The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes. 1994 ; 43: 1180-1184
53. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by angiotensin II. Methods Find Exp Clin Pharmacol. 2000 ; 22: 709-723
54. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes. 2001 ; 50: 1414-1424
55. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-β1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997 ; 29: 1947-1958
56. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-β 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol. 1995 ; 27: 2347-2357
57. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000 ; 101: 899-907
58. Koya D, Dennis JW, Warren CE, Takahara N, Schoen FJ, Nishio Y, et al. Overexpression of core 2 N-acetylglycosaminyltransferase enhances cytokine actions and induces hypertrophic myocardium in transgenic mice. FASEB J. 1999 ; 13 (15). 2329-2337
59. Thandavarayan RA, Watanabe K, Ma M, Veeraveedu PT, Gurusamy N, Palaniyandi SS, et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol. 2008 ; 75 (9). 1797-806
60. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res. 1989 ; 65: 657-670
61. Buja LM, Willerson JT. The role of coronary artery lesions in ischemic heart disease: insights from recent clinicopathologic, coronary arteriographic and experimental studies. Hum Pathol. 1987 ; 18: 451-461
62. Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels. 1985 ; 1: 43-47
63. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci. 2001 ; 69: 527-542
64. Howarth FC, Qureshi MA, Lawrence P, Adeghate E. Chronic effects of streptozotocin-induced diabetes on the ultrastructure of rat ventricular and papillary muscle. Acta Diabetol. 2000 ; 37: 119-124
65. Shimizu M. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol. 1993 ; 46: 32-36
66. Sutherland CG. Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. Histopathology. 1989 ; 14: 593-602
67. Fang Z, Najos-Valencia O, Leano R, Marwick T. Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol. 2003 ; 42: 446-453
68. Warley A, Powell JM, Skepper JN. Capillary surface area is reduced and tissue thickness from capillaries to myocytes is increased in the left ventricle of streptozotocin-diabetic rats. Diabetologia. 1995 ; 38: 413-421
69. Factor SM. Coronary microvascular abnormalities in the hypertensive-diabetic rat. A primary cause of cardiomyopathy?. Am J Pathol. 1984 ; 116: 9-20
70. Sonnenblick EH, Fein F, Capasso JM, Factor SM. Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. Am J Cardiol. 1985 ; 55: 179B - 184B
71. Kawaguchi M. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with and without diabetes mellitus with and without hypertension. Heart Vessels. 1997 ; 12: 267-274
72. Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA. 1974 ; 229: 1749-1754
73. Blumenthal HT, Alex M, Goldenberg S. A study of lesions of the intramural coronary branches in diabetes mellitus. Arch Pathol. 1960 ; 70: 27-42
74. Sunni S, Bishop SP, Kent SP, Geer JC. Diabetic Cardiomyopathy. A morphologic study of intramyocardial arteries. Arch Pathol Lab Med. 1986 ; 110: 375-381
75. Nitenberg A, Foult JM, Blanchet F, Zouioueche S. Multifactorial determinants of reduced coronary flow reserve after dipyridamole in dilated cardiomyopathy. Am J Cardiol. 1985 ; 55: 748-754
76. Nitenberg A. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993 ; 42: 1017-1025
77. Strauer BE, Motz W, Vogt M, Schwartzkopff B. Impaired coronary flow reserve in NIDDM: a possible role for diabetic cardiopathy in humans. Diabetes. 1997 ; 46: S119 - S124
78. Treasure CB. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990 ; 81: 772-779
79. Durante W, Sunahara FA, Sen AK. Effect of diabetes on metabolic coronary dilatation in the rat. Cardiovasc Res. 1989 ; 23: 40-45
80. Yokoyama I. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes. 1998 ; 47: 119-124
81. Pitkanen OP. Coronary flow reserve is reduced in young men with IDDM. Diabetes. 1998 ; 47: 248-254
82. Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes mellitus. Am J Cardiol. 1997 ; 80: 94A - 101A
83. Regan TJ. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest. 1977 ; 60: 884-899
84. Sakamoto K. Mechanism of impaired left ventricular wall motion in the diabetic heart without coronary artery disease. Diabetes Care. 1998 ; 21: 2123-2128
85. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol. 1991 ; 260: H319 - H326
86. Taylor PD, Graves JE, Poston L. Selective impairment of acetylcholine-mediated endothelium-dependent relaxation in isolated resistance arteries of the streptozotocin-induced diabetic rat. Clin Sci (Lond). 1995 ; 88: 519-524
87. Johnstone MT. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993 ; 88: 2510-2516
88. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 1991 ; 87: 1643-1648
89. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998 ; 47: 859-866
90. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium dependent vasodilatation in experimental diabetes. J Clin Invest. 1991 ; 87: 432-438
91. Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol. 1991 ; 261: H1086 - H1094
92. Joffe II. Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with Doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol. 1999 ; 34: 2111-2119
93. Pieper GM, Langenstroer P, Gross GJ. Hydroxyl radicals mediate injury to endothelium-dependent relaxation in diabetic rat. Mol Cell Biochem. 1993 ; 122: 139-145
94. Rosen P, Ballhausen T, Bloch W, Addicks K. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia. 1995 ; 38: 1157-1168
95. Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am J Physiol. 1989 ; 257: H1327 - H1333
96. Uekita K, Tobise K, Onodera S. Enhancement of the cardiac β-adrenergic system at an early diabetic state in spontaneously diabetic Chinese hamsters. Jpn Circ J. 1997 ; 61: 64-73
97. Felten SY. Effects of streptozotocin diabetes on the noradrenergic innervation of the rat heart: a longitudinal histofluorescence and neurochemical study. Brain Res Bull. 1982 ; 8: 593-607
98. Pietrzyk Z, Vogel S, Dietze GJ, Rabito SF. Augmented sympathetic response to bradykinin in the diabetic heart before autonomic denervation. Hypertension. 2000 ; 36: 208-214
99. Manzella D. Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab. 2001 ; 86: 2769-2
100. Kondo K, Matsubara T, Nakamura J, Hotta N. Characteristic patterns of circadian variation in plasma catecholamine levels, blood pressure and heart rate variability in type 2 diabetic patients. Diabet Med. 2002 ; 19: 359-365
101. Ahlborg G, Lundberg JM. Exercise-induced changes in neuropeptide Y, noradrenaline and endothelin-1 levels in young people with type I diabetes. Clin Physiol. 1996 ; 16: 645-655
102. Communal C, Singh K, Pimentel DR, Colucci WS. Orepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation. 1998 ; 98: 1329-1334
103. Iwai-Kanai E. α- and β-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation. 1999 ; 100: 305-311
104. Shizukuda Y. β-Adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol. 1998 ; 275: H961 - H968
105. Khorchid A, Fragoso G, Shore G, Almazan G. Catecholamine-induced oligodendrocyte cell death in culture is developmentally regulated and involves free radical generation and differential activation of caspase-3. Glia. 2002 ; 40: 283-299
106. Tappia PS. Role of oxidative stress in catecholamine-induced changes in cardiac sarcolemmal Ca2+ transport. Arch Biochem Biophys. 2001 ; 387: 85-92
107. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999 ; 99: 2934-2941
108. el Hage AN, Herman EH, Jordan AW, Ferrans VJ. Influence of the diabetic state on isoproterenol-induced cardiac necrosis. J Mol Cell Cardiol. 1985 ; 17: 361-369
109. Qin F, et al. Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepinephrine infusion in ferrets. Cardiovasc Res. 2001 ; 51: 736-748
110. Bisognano JD. Myocardial-directed overexpression of the human β(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000 ; 32: 817-830
111. Singh K. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol. 2001 ; 189: 257-265
112. Irlbeck M, Zimmer HG. Functional responses of the left and right heart of diabetic rats to α- and β-adrenergic receptor stimulation. Diabetes Res Clin Pract. 1996 ; 31: S79 - S86
113. Erbas T. Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus. Clin Cardiol. 2000 ; 23: 259-263
114. Rajan SK, Gokhale SM. Cardiovascular function in patients with insulin-dependent diabetes mellitus: a study using noninvasive methods. Ann NY Acad Sci. 2002 ; 958: 425-430
115. Kahn JK, Zola B, Juni JE, Vinik AI. Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy. J Am Coll Cardiol. 1986 ; 7: 1303-1309
116. Erbas T. Scintigraphic evaluation of left ventricular function and correlation with autonomic cardiac neuropathy in diabetic patients. Cardiology. 1992 ; 81: 14-24
117. Scognamiglio R. Myocardial dysfunction and abnormal left ventricular exercise response in autonomic diabetic patients. Clin Cardiol. 1995 ; 18: 276-282
118. Kreiner G. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes. 1995 ; 44: 543-549
119. Taskiran M. Decreased myocardial perfusion reserve in diabetic autonomic neuropathy. Diabetes. 2002 ; 51: 3306-3310
120. Scognamiglio R. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998 ; 31: 404-412
121. Hoit BD, Castro C, Bultron G, Knight S, Matlib MA. Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail. 1999 ; 5: 324-333
122. Lind L, Berne C, Anden B, Lithell H. Relationship between diastolic hypertension and myocardial morphology and function in elderly males with diabetes mellitus. Diabetologia. 1996 ; 39: 1603-1606
123. Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type-1 diabetic patients. Diabetes Care. 1994 ; 17: 633-639
124. Brown RA, Filipovich P, Walsh MF, Sowers JR. Influence of sex, diabetes and ethanol on intrinsic contractile performance of isolated rat myocardium. Basic Res Cardiol. 1996 ; 91: 353-360
125. Dent CL. Echocardiographic characterization of fundamental mechanisms of abnormal diastolic filling in diabetic rats with a parameterized diastolic filling formalism. J Am Soc Echocardiogr. 2001 ; 14: 1166-1172
126. Flarsheim CE, Grupp IL, Matlib MA. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol. 1996 ; 271: H192 - H202
127. Poirier P. Diastolic dysfunction in normotensive men with well controlled type-2 diabetes: importance of manoeuvers in echocardiographic screening for pre-clinical diabetic cardiomyopathy. Diabetes Care. 2001 ; 24: 5-10
128. Schannwell CM. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology. 2002 ; 98: 33-39
129. Fang ZY. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol. 2003 ; 41: 611-617
130. Astori E. Isolated and Preclinical impairment of left ventricular filling in insulin-dependent and non-insulin dependent diabetes mellitus. Clin Cardiol. 1997 ; 20: 536-540
131. Wold LE. Characterization of contractile function in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes. J Mol Cell Cardiol. 2001 ; 33: 1719-1726
132. Hayashi K. Involvement of 1,2-diacylglycerol in improvement of heart function by etomoxir in diabetic rats. Life Sci. 2001 ; 68: 1515-1526
133. Coughlin SS. Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington DC, Dilated Cardiomyopathy Study. Ann Epidemiol. 1994 ; 4: 67-74
134. Mbanya JC, Sobngwi E, Mbanya DS, Nug KB. Left Ventricular mass and systolic function in African diabetic patients: association with microalbuminuria. Diabetes Metab. 2001 ; 27: 378-382
135. Vered A. Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). Am J Cardiol. 1984 ; 54: 633-637
136. Bhimji S, Godin DV, McNeill JH. Myocardial ultrastructural changes in alloxan-induced diabetes in rabbits. Acta Anat (Basel). 1986 ; 125: 195-200
137. Eto M. Metabolic and morphological changes of the heart in Chinese hamsters (CHAD strain) with spontaneous long-term diabetes. Diabetes Res Clin Pract. 1987 ; 3: 297-305
138. Kerut EK. Echocardiographic texture analysis using the wavelet transform: differentiation of early heart muscle disease. Ultrasound Med Biol. 2000 ; 26: 1445-1453
139. Di Bello V. Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. J Am Coll Cardiol. 1995 ; 25: 1408-1415
140. Picano E. In vivo quantitive ultrasonic evaluation of myocardial fibrosis in humans. Circulation. 1990 ; 81: 58-64
141. van Hoven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic and hypertensive-diabetic heart disease. Circulation. 1990 ; 82: 848-855
142. Howarth FC, Qureshi MA, White E, Calaghan SC. Cardiac microtubules are more resistant to chemical depolymerisation in streptozotocin-induced diabetes in the rat. Pflugers Arch. 2002 ; 444: 432-437
143. Das AK, Das JP, Chandrasekar S. Specific heart muscle disease in diabetes mellitus-a functional structural correlation. Int J Cardiol. 1987 ; 17: 299-302
144. Zoneraich S. Small-vessel disease, coronary artery vasodilator reserve, and diabetic cardiomyopathy. Chest. 1988 ; 94: 5-7
145. Harrower AD, Small DR, Railton R. Variability of left ventricular function at diagnosis and after treatment in insulin-dependent diabetes. Diabetes Res. 1986 ; 3: 149-152
146. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L.. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol. 2001 ; 133: 687-694
147. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation. 1996 ; 93: 1905-1912